Insmed Inc (INSM) concluded trading on Wednesday at a closing price of $104.59, with 3.69 million shares of worth about $386.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 51.73% during that period and on July 16, 2025 the price saw a gain of about 1.67%. Currently the company’s common shares owned by public are about 189.95M shares, out of which, 185.73M shares are available for trading.
Stock saw a price change of 8.42% in past 5 days and over the past one month there was a price change of 5.94%. Year-to-date (YTD), INSM shares are showing a performance of 36.34% which increased to 51.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.40 but also hit the highest price of $106.83 during that period. The average intraday trading volume for Insmed Inc shares is 3.77 million. The stock is currently trading 4.18% above its 20-day simple moving average (SMA20), while that difference is up 24.14% for SMA50 and it goes to 37.21% higher than SMA200.
Insmed Inc (NASDAQ: INSM) currently have 189.95M outstanding shares and institutions hold larger chunk of about 104.71% of that.
The stock has a current market capitalization of $19.87B and its 3Y-monthly beta is at 0.95. It has posted earnings per share of -$5.95 in the same period. It has Quick Ratio of 5.44 while making debt-to-equity ratio of 13.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INSM, volatility over the week remained 3.50% while standing at 3.01% over the month.
Stock’s fiscal year EPS is expected to rise by 6.26% while it is estimated to increase by 30.05% in next year. EPS is likely to grow at an annualized rate of 48.30% for next 5-years, compared to annual growth of -13.12% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on May 13, 2025 offering a Buy rating for the stock and assigned a target price of $105 to it. Coverage by RBC Capital Mkts stated Insmed Inc (INSM) stock as an Outperform in their note to investors on February 25, 2025, suggesting a price target of $100 for the stock. On April 23, 2024, Truist Initiated their recommendations, while on February 15, 2024, Wolfe Research Initiated their ratings for the stock with a price target of $42. Stock get an Overweight rating from Wells Fargo on December 08, 2023.
